Anti-Human Tissue Factor Antibody Ameliorated Intestinal Ischemia Reperfusion-Induced Acute Lung Injury in Human Tissue Factor Knock-In Mice
Open Access
- 30 January 2008
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 3 (1), e1527
- https://doi.org/10.1371/journal.pone.0001527
Abstract
Interaction between the coagulation and inflammation systems plays an important role in the development of acute respiratory distress syndrome (ARDS). Anti-coagulation is an attractive option for ARDS treatment, and this has promoted development of new antibodies. However, preclinical trials for these antibodies are often limited by the high cost and availability of non-human primates. In the present study, we developed a novel alternative method to test the role of a humanized anti-tissue factor mAb in acute lung injury with transgenic mice. Human tissue factor knock-in (hTF-KI) transgenic mice and a novel humanized anti-human tissue factor mAb (anti-hTF mAb, CNTO859) were developed. The hTF-KI mice showed a normal and functional expression of hTF. The anti-hTF mAb specifically blocked the pro-coagulation activity of brain extracts from the hTF-KI mice and human, but not from wild type mice. An extrapulmonary ARDS model was used by intestinal ischemia-reperfusion. Significant lung tissue damage in hTF-KI mice was observed after 2 h reperfusion. Administration of CNTO859 (5 mg/kg, i.v.) attenuated the severity of lung tissue injury, decreased the total cell counts and protein concentration in bronchoalveolar lavage fluid, and reduced Evans blue leakage. In addition, the treatment significantly reduced alveolar fibrin deposition, and decreased tissue factor and plasminogen activator inhibitor-1 activity in the serum. This treatment also down-regulated cytokine expression and reduced cell death in the lung. This novel anti-hTF antibody showed beneficial effects on intestinal ischemia-reperfusion induced acute lung injury, which merits further investigation for clinical usage. In addition, the use of knock-in transgenic mice to test the efficacy of antibodies against human-specific proteins is a novel strategy for preclinical studies.Keywords
This publication has 42 references indexed in Scilit:
- Expression of human tissue factor under the control of the mouse tissue factor promoter mediates normal hemostasis in knock-in miceJournal of Thrombosis and Haemostasis, 2008
- INTESTINAL ISCHEMIA-REPERFUSION-INDUCED ACUTE LUNG INJURY AND ONCOTIC CELL DEATH IN MULTIPLE ORGANSShock, 2007
- The alveolar epithelium can initiate the extrinsic coagulation cascade through expression of tissue factorThorax, 2007
- Lipopolysaccharide accelerates caspase‐independent but cathepsin B‐dependent death of human lung epithelial cellsJournal of Cellular Physiology, 2006
- Src protein tyrosine kinase family and acute inflammatory responsesAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2006
- Local activation of the tissue factor-factor VIIa pathway in patients with pneumonia and the effect of inhibition of this pathway in murine pneumococcal pneumonia*Critical Care Medicine, 2006
- Blockade of tissue factor-factor X binding attenuates sepsis-induced respiratory and renal failureAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2006
- Regulation of chemotaxis by the cytoplasmic domain of tissue factorThrombosis and Haemostasis, 2005
- The Acute Respiratory Distress SyndromeNew England Journal of Medicine, 2000
- The coagulation cascade: initiation, maintenance, and regulationBiochemistry, 1991